Adam H. Golden is a Partner in and Co-Chair of Kaye Scholer’s Corporate Department. His practice focuses on mergers and acquisitions, securities offerings, intellectual property licenses, joint ventures and other corporate partnering transactions. He has represented companies in the pharmaceutical and biotechnology, private equity, infrastructure, chemicals, consumer products, technology, software, healthcare services, medical devices, defense, finance and alternative asset management industries. Adam’s clients range in size from multibillion-dollar global businesses to emerging-stage companies.
Adam has substantial experience representing clients for whom intellectual property is a key asset. As a lawyer with a background in science, he brings an in-depth understanding of the technology involved in transactions for the benefit of his clients. A particular focus is in the area of life sciences, where he heads the firm’s Life Sciences Transactions Group and has broad experience in the full range of licensing and collaboration transactions common to this sector.
Adam has been recognized as a leading practitioner in Chambers USA: America’s Leading Lawyers for Business (2009-2013) and Legal 500 US and is recognized as a Life Science Star in LMG Life Sciences (2012-2013). He has also been recognized in the IAM Patent 1000 – The World’s Leading Patent Practitioners (2012-2013) for his IP licensing skill.
Recent Representative Matters
- Novartis in numerous M&A and licensing transactions, including most recently the acquisition of Fougera Pharmaceuticals from a consortium of private equity funds for $1.525 billion and a global licensing and collaboration agreement with Regenerex LLC.
- Parsons Brinckerhoff in the sale of this infrastructure engineering and design firm to Balfour Beatty for $626 million.
- Pfizer in numerous M&A and licensing transactions, including most recently the acquisition of NextWave Pharmaceuticals for up to $700 million and an exclusive worldwide license agreement with Gliknik Inc.
- Principal stockholder of iMDsoft in its sale to TPG Capital.
- Vatera Healthcare in venture capital investments in biopharmaceutical companies, including most recently in ImmusanT, Inc. and Ekteino Laboratories Inc.
- Columbia Laboratories in numerous securities offerings and other transactions, including most recently the sale of its progesterone-related assets and common stock to Watson Pharmaceuticals for up to approximately $110 million.
- Wacker Chemie AG in its acquisition of Air Products’ interests in two polymers joint ventures for $265 million.